Tenet Healthcare (NYSE:THC) Issues FY 2026 Earnings Guidance

Tenet Healthcare (NYSE:THC) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 16.190-18.470 for the period, compared to the consensus earnings per share estimate of 16.540. The company issued revenue guidance of $21.5 billion-$22.3 billion, compared to the consensus revenue estimate of $21.8 billion.

Tenet Healthcare Price Performance

Shares of NYSE THC traded up $29.71 during midday trading on Wednesday, reaching $222.75. 1,291,535 shares of the company traded hands, compared to its average volume of 949,661. The firm has a market cap of $19.58 billion, a PE ratio of 15.27, a PEG ratio of 0.82 and a beta of 1.44. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.64 and a current ratio of 1.71. The stock’s 50-day simple moving average is $197.70 and its 200-day simple moving average is $193.68. Tenet Healthcare has a 12 month low of $109.82 and a 12 month high of $222.99.

Tenet Healthcare (NYSE:THC) last released its quarterly earnings results on Wednesday, February 11th. The company reported $4.70 EPS for the quarter, beating analysts’ consensus estimates of $4.05 by $0.65. Tenet Healthcare had a net margin of 6.49% and a return on equity of 25.11%. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the firm earned $3.44 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. As a group, equities analysts anticipate that Tenet Healthcare will post 12.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on THC. The Goldman Sachs Group began coverage on Tenet Healthcare in a report on Tuesday, October 14th. They set a “buy” rating and a $224.00 price target for the company. Morgan Stanley restated an “overweight” rating and issued a $247.00 target price on shares of Tenet Healthcare in a research note on Thursday, December 18th. Wall Street Zen upgraded shares of Tenet Healthcare from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. UBS Group restated a “buy” rating on shares of Tenet Healthcare in a research report on Tuesday, February 3rd. Finally, TD Cowen reiterated a “buy” rating on shares of Tenet Healthcare in a research report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $233.88.

Insider Transactions at Tenet Healthcare

In other Tenet Healthcare news, Director Nadja West sold 2,178 shares of Tenet Healthcare stock in a transaction on Monday, December 15th. The shares were sold at an average price of $197.47, for a total transaction of $430,089.66. Following the completion of the sale, the director owned 28,480 shares of the company’s stock, valued at approximately $5,623,945.60. The trade was a 7.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.81% of the company’s stock.

Trending Headlines about Tenet Healthcare

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Q4 EPS beat and year‑over‑year improvement: Tenet reported $4.70 EPS for Q4 (vs. ~\$4.05–4.08 consensus) and $3.44 a year ago, signaling better profitability and operational leverage. Tenet Healthcare (THC) Q4 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Revenue growth, margins and cash flow strengthened: Revenue rose ~8.9% YoY, net margin and ROE improved, and management highlighted robust free cash flow and continued demand for acute/ambulatory services. These fundamentals support valuation and investor confidence. Tenet Reports Strong Fourth Quarter and FY 2025 Results; Provides 2026 Financial Outlook
• Neutral Sentiment: Company issued FY‑2026 guidance: Tenet gave an EPS range of 16.190–18.470 and revenue guidance of $21.5B–$22.3B. The range gives direction for 2026 but leaves room for variability; investors will watch execution against that span. Tenet Reports Strong Fourth Quarter and FY 2025 Results; Provides 2026 Financial Outlook
• Negative Sentiment: Guidance is mixed vs. Street: The EPS range’s midpoint is slightly below consensus (~16.54) and the revenue band is marginally under street expectations, which could cap near‑term upside despite the beat. Compared to Estimates, Tenet (THC) Q4 Earnings: A Look at Key Metrics
• Negative Sentiment: Operational headwinds flagged pre‑earnings: Analysts had noted risks from lower hospital patient days that could pressure margins if volumes soften — a factor to monitor in upcoming quarters. Will Lower Patient Days Affect Tenet Healthcare’s Q4 Earnings?

Hedge Funds Weigh In On Tenet Healthcare

Several hedge funds have recently added to or reduced their stakes in THC. Triumph Capital Management acquired a new position in shares of Tenet Healthcare during the 3rd quarter worth about $25,000. Canada Pension Plan Investment Board bought a new position in Tenet Healthcare during the 2nd quarter worth approximately $35,000. Geneos Wealth Management Inc. increased its stake in Tenet Healthcare by 50.9% in the second quarter. Geneos Wealth Management Inc. now owns 264 shares of the company’s stock valued at $46,000 after purchasing an additional 89 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Tenet Healthcare in the second quarter worth $65,000. Finally, Virtus Advisers LLC boosted its position in shares of Tenet Healthcare by 300.0% during the third quarter. Virtus Advisers LLC now owns 512 shares of the company’s stock worth $104,000 after purchasing an additional 384 shares in the last quarter. Institutional investors and hedge funds own 95.44% of the company’s stock.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.